Human Papilloma Virus InfectionNCT02067507
Increasing Human Papillomavirus Vaccine Uptake in Low-Income, Ethnic Minority Adolescents in Los Angeles County
A study testing Tailored education and referral, Staff training and patient reminders and Clinic-level reminder systems in people with Human Papilloma Virus Infection, run by University of California, Los Angeles at 2 sites in United States.
Trial summary
The primary aim of the project is to increase human papillomavirus (HPV) vaccine receipt rates among low-income, ethnic minority adolescents (girls and boys 11-17 years of age) in Los Angeles County. Read more about this study
- Who is it for?
- Ages 9 to 70 years
- Conditions the study is for
- Human Papilloma Virus Infection
- What is being tested?
- Tailored education and referral, Staff training and patient reminders and Clinic-level reminder systems
- Type of treatment
- Vaccines, Lifestyle or therapy programme
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 53,414 participants
- Where
- 2 sitesUnited States
- Study dates
- Jun 2012to Oct 2019
- Phase
- Interventional
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 9 to 70 years
- All sexes
- No healthy volunteers
- Child, Adult, Older adult
Who may be able to join
- Adult male or female
- Current or previous user of the Los Angeles County Office of Women's Health Hotline
- Speaks one of the hotline languages (English, Spanish, Korean, Mandarin, Cantonese, Armenian)
- Is the medical decision-maker for a male or female adolescent aged 11-17 in his or her home
- Adolescent has not started the HPV vaccine series
- Current resident of Los Angeles County
Show all 11Show fewer
- Adolescent male or female (9-17 years)
- Has received at least one service at the FQHC in the past 2 years
- Adolescent male or female (12-13 years)
- Has received at least one service at the FQHC in the past 2 years
- Has received no doses or 1 dose of the HPV vaccine
Who cannot join
- Younger than 18 or older than 70 years of age
- Not conversant in one of the hotline languages (English, Spanish, Korean, Mandarin, Cantonese, Armenian)
- Is not the medical decision-maker for an adolescent aged 11-17 in his or her home
- Adolescent has initiated the HPV vaccine series
- Not a current resident of Los Angeles County
- Recruitment Venue 2 (AltaMed) Criteria:
Show all 12Show fewer
- Younger than 9 or older than 17 years of age
- Has not received any services at the FQHC in the past 2 years
- Recruitment Venue 3 (NEVHC) Criteria:
- Younger than 12 or older than 13 years of age
- Has not received any services at the FQHC in the past 2 years
- Has completed the 3-dose HPV vaccine
Trial locations and contacts
2 sites in 1 country.
United States2 sites
Los Angeles County Department of Public Health
Alhambra, California, 91803
Northeast Valley Health Corporation
San Fernando, California, 91340
About this study
The primary aim of the project is to increase human papillomavirus (HPV) vaccine receipt rates among low-income, ethnic minority adolescents (girls and boys 11-17 years of age) in Los Angeles County. We will accomplish this goal by implementing and rigorously evaluating interventions in multiple venues that serve our target population, including the Los Angeles County Department of Public Health (LACDPH) and two large Federally Qualified Health Centers (FQHCs).
Our hypotheses are:
Read more
Primary hypothesis:
- The intervention group will have a higher rate of HPV vaccine initiation at follow-up compared to the control group. Secondary hypothesis:
- The intervention group will have higher vaccine completion rates (3 doses) at follow-up compared to the control group.
Read the detailed description
The primary aim of the project is to increase HPV vaccine receipt rates among low-income, ethnic minority adolescents (girls and boys ages 9-17 years) in LA County. We will accomplish this goal by implementing and rigorously evaluating interventions in multiple venues that serve our target population, including the Los Angeles County Department of Public Health (LACDPH) and two large Federally Qualified Health Centers (FQHCs).
Our hypotheses are:
Primary hypothesis:
- The intervention group will have a higher rate of HPV vaccine initiation at follow-up compared to the control group. Secondary hypothesis:
- The intervention group will have higher vaccine completion rates (3 doses) at follow-up compared to the control group.
Recruitment Venue 1: Los Angeles County Department of Public Health. At the LACDPH, the multi-component intervention will be directed at caregivers of age-eligible adolescents (11-17 years) and include brief individually-tailored telephone education, referral to a clinic offering low cost/free vaccine, and a mailed brochure. The control group will receive usual care and a standard Centers for Disease Control and Prevention (CDC) HPV vaccine fact sheet.
Additional secondary hypotheses for this recruitment venue include:
- The intervention group will have higher knowledge of HPV and the HPV vaccine than the control group.
- The intervention will have a greater effect on the more acculturated than less acculturated participants (moderator effect).
- The intervention will exert its effect on vaccine receipt by increasing knowledge and reducing barriers (mediator effects).
This recruitment venue will utilize a two-arm time-randomized (on-off) controlled design to assess the effect of a multi-component intervention targeting mothers and fathers, to increase HPV vaccine uptake among their adolescents (ages 11-17). Hotline users will be randomized into the intervention or control condition on an alternating (on/off) weekly schedule. Eligible participants will complete a baseline telephone interview. Immediately following the baseline interview, participants calling during intervention weeks will receive the individually-tailored multi-component intervention, including tailored education and clinic referral. A tailored print intervention will also be mailed to intervention participants. All participants will be re-contacted at 3 months and 9 months for telephone follow-up interviews. Control group participants will receive the intervention after the 9-month follow-up. Prior to study protocol implementation, about 25-50 individuals will be recruited to pre-test the baseline survey in different languages (English, Spanish, Chinese, Armenian) to ensure the baseline questionnaires are similar in content across languages and the questions are clear.
The study site will enroll men and women of diverse racial-ethnic backgrounds from the Office of Women's Health (OWH) women's health telephone hotline database. The database includes contact information about adult women LA County residents who telephoned a 1-800 hotline to receive information and referrals about women's health issues, including cervical cancer and cervical cancer screening. Male callers also use the hotline. The OWH has promoted the hotline through partnerships with over 300 community-based organizations. Recruitment of callers from the database will consist of operators calling women to invite them to be screened for study eligibility. Recruitment of new hotline callers will take place during their first contact with the hotline. Upon receiving an incoming call, operators will first respond to the caller's request using routine hotline protocols which include screening for income eligibility (<200% of poverty) for county services. Following this, operators invite the caller to be screened for study eligibility. Eligible participants will be asked to complete the baseline interview.
Callers will be randomized to the intervention or control condition on alternating weeks (on-off or time randomized design). This randomization scheme was selected in close consultation with OWH to ensure the integrity of the randomization process and minimize disruption of routine hotline operation. The telephone intervention will be delivered immediately following the baseline telephone interview to participants calling during intervention weeks. The intervention is based on the Health Behavior Framework and pilot study findings and incorporates individual-level tailoring. The three segments of the telephone intervention include: 1) basic information about the HPV vaccine; 2) individually-tailored information to address each participant's primary concerns regarding the vaccine; 3) individually-tailored referral to a local clinic where free/low cost vaccine is available.
Baseline interviews (10-15 mins) will be conducted immediately following the eligibility screener and the verbal informed consent, via a Computer Assisted Telephone Interviewing System. All eligible subjects who complete the baseline interview will receive brief (<10 mins) 3 and 9-month follow-up telephone interviews.
Following the 3-month interviews, half of intervention participants will receive a "booster" intervention wherein we will repeat the clinic referral procedure/language given during the intervention at baseline. Intervention participants will be randomized to the "booster" or no "booster" condition based on the order in which they completed the baseline survey.
Recruitment Venue 2: AltaMed Health Services Corporation. At AltaMed Health Services Corporation, the largest federally qualified health center in the nation, we will implement a multi-level intervention that includes patient (i.e., caregiver) and provider reminders, physician, nurse, and other staff training regarding the HPV vaccine and processes and procedures for its delivery. We will utilize a quasi-experimental study design to assess the effect of this multi-level intervention to increase HPV vaccine initiation and completion among adolescents (ages 9-17). Eight clinic sites that serve the majority of AltaMed's adolescent population will be matched based on the size of the adolescent population served and baseline HPV vaccination rates. We will randomly assign matched paired clinics to either the intervention (n=4) or usual care group (n=4).
Clinics assigned to the usual care condition will only receive: (1) the standing order for the HPV vaccine, which authorizes non-physician providers to assess adolescents' immunization eligibility and administer the HPV vaccine without a physician examination or order and (2) a required web-based training module for medical assistants and nurses containing basic information on HPV, the HPV vaccine, and standing order implementation.
In addition to usual care activities, intervention clinics will receive the following: (1) health care provider training on the importance of HPV vaccination and a strong provider recommendation, strategies to appropriately frame the HPV vaccine conversation, and recommended processes and procedures for vaccine delivery; (2) staff training on the importance of HPV vaccination, strategies to promote uptake of the vaccine, and recommended processes and procedures for vaccine delivery; (3) patient and provider reminders to promote completion of the three-dose vaccine series; and (4) organizational strategies to improve processes for vaccine delivery, in addition to usual care activities.
The intervention will be developed in close collaboration with administrative leadership and providers, who will provide input at each stage of the design, implementation, and evaluation process. A physician vaccine champion from the organization will assist with the development of and lead a one-hour, in-person provider presentation and discussion. For the staff training presentation, nurse managers will be convened regularly to discuss processes for HPV and general standing order implementation, strategies to optimize clinical workflow and increase follow-up, and development of back office staff training. Using a train-the-trainer approach, the nurse mangers will lead the approximate one-hour presentation and discussion at their respective clinics. They will also monitor process implementation through direct staff observation and quality reports and retrain staff as needed.
In addition to provider and staff trainings, organizational strategies at intervention sites will include implementation of standard practices for HPV vaccine delivery that complement existing clinical workflow. At intake, back office staff will check vaccination history at each visit, implement needed standing orders, inform caregivers of vaccines due, and notify the provider of vaccines ordered. During the provider encounter, providers will confirm recommended vaccinations and recommend the HPV vaccine as part of other routine vaccines. At check-out, back office staff will administer vaccines, schedule a visit for the second dose, and provide caregivers both a standard appointment card and an intervention site reminder magnet. A clinic provider vaccine champion will be identified to monitor implementation, adapt processes, and serve as a resource at intervention sites.
To estimate intervention effects, we will use data extracted from AltaMed's electronic medical record system to measure HPV vaccine initiation and completion rates among adolescents ages 9-17 at baseline and at regular intervals post intervention implementation. Patient, provider and clinic factors associated with vaccine receipt will also be examined.
Recruitment Venue 3: Northeast Valley Health Corporation. At Northeast Valley Health Corporation, another large federally qualified health center, we will implement and evaluate the effects of three different clinic-level reminder systems (mailed letter, automated/robo telephone call, text message) on HPV vaccine initiation and completion among adolescents (ages 12-13).
We will utilize a quasi-experimental study design. This FQHC comprises 8 sites that provide primary care for medically underserved adults and adolescents in LA County. We will select 6 clinics matched on baseline vaccine receipt rates and other clinic characteristics and randomly assign matched paired clinics to usual care or one of the three reminder system interventions: mailed letter, automated/robo telephone call, or text message. Eligible caregivers of adolescent boys and girls ages 12-13 who have received no doses or only one dose of the HPV vaccine will be identified through Northeast Valley's electronic medical record and population health management systems.
After identification of eligible patients (i.e. caregivers), the centralized call center will generate a standard letter and the automated/robocalls. A third-party vendor will send the text messages. The reminder content will be adapted from existing clinical message scripts and include a short message, which will be consistent across all modalities, on the importance of HPV vaccination and how to make an appointment. Reminder messages will be delivered in the patients' preferred language (either English or Spanish). The same reminder type (either letter, call, or text message) will be used on up to two occasions: once at baseline and a second time approximately one month after baseline for those who have not yet received the targeted vaccine dose. To monitor receipt of reminders, number of unaccepted telephone calls, returned letters, and stopped text messages will be monitored. Clinics assigned to the usual care condition will receive standard of care, which does not include any systematic reminders.
Similar to the AltaMed FQHC site, to estimate intervention effects, we will use data extracted from electronic medical records to measure HPV vaccine initiation and completion rates at baseline and at regular intervals post intervention implementation.
- Conditions
- Human Papilloma Virus Infection
- Being tested
- Tailored education and referral, Staff training and patient reminders, Clinic-level reminder systems
- Keywords
- Human Papillomavirus, Immunization, Oncogenic viruses, Cervical Cancer, Health Disparities
- Medical subject headings
- Papillomavirus Infections, Uterine Cervical Neoplasms
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Tailored education and referralBehavioural
LACDPH Site: 5-minute tailored educational messages and clinic referral for vaccine plus tailored small media
Staff training and patient remindersBehavioural
AltaMed Health Services Corporation Site: (1) Health care provider training on the importance of HPV vaccination, strategies to appropriately frame the HPV vaccine conversation, and recommended processes and procedures for vaccine delivery; (2) Staff training on the importance of HPV vaccination, strategies to promote uptake of the vaccine, and recommended processes and procedures for vaccine delivery; (3) Patient reminders and provider cues for follow-up doses; and (4) Organizational strategies to improve processes for vaccine delivery, in addition to usual care activities
Clinic-level reminder systemsBehavioural
Northeast Valley Health Corporation Site: Three different clinic-level reminder systems, including a mailed letter, automated/robo telephone call, or text message reminder
| Study group | Role | What they receive |
|---|---|---|
| Control | No intervention | LACDPH Site: CDC-developed small media in preferred language AltaMed Health Services Corporation Site: Usual care - Standing order for the HPV vaccine; required web-based training module for medical assistants and nurses containing basic information on HPV, the HPV vaccine, and standing order implementation Northeast Valley Health Corporation Site: Usual care |
| Tailored education and referral | Experimental | LACDPH Site: Tailored education and referral intervention administered at LACDPH Site Receives: Behavioral: Tailored education and referral |
| Staff training and patient reminders | Experimental | Staff training and patient reminders administered at AltaMed Health Services Corporation Site Receives: Behavioral: Staff training and patient reminders |
| Clinic-level reminder systems | Experimental | Clinic-level reminders administered at Northeast Valley Health Corporation Site Receives: Behavioral: Clinic-level reminder systems |
What is being measured
The primary outcome is the main question the study is designed to answer.
HPV Vaccine Uptake
The receipt of one or more doses of the HPV vaccine
Measured: 3 months, 6 months
Secondary outcomes (1)
HPV Vaccine Series Completion
Completion of the 3-dose HPV vaccine series
Measured: 9 months, 12 months
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted20 Feb 2014 (estimated)
- Study startJun 2012
- Primary completionOct 2019
- Study completionOct 2019
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Human Papilloma Virus InfectionStudies of the same condition, open and under way.
- More trials run by University of California, Los AngelesThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Prevention
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- None (open label)
- Enrolment
- 53,414 participants (actual)
Sponsor and investigators
- Lead sponsor
- University of California, Los Angeles
- Sponsor type
- University, hospital or other
- Collaborators
- Los Angeles County Department of Public Health
- Responsible party
- Principal investigator, Roshan Bastani, University of California, Los Angeles
- Investigators
- Roshan Bastani, PhD, Principal investigator, University of California, Los AngelesBeth Glenn, PhD, Study director, University of California, Los Angeles
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT02067507
- Sponsor's protocol ID
- R01CA154549-01A1
- Status last verified
- Oct 2019
- First submitted
- 18 Feb 2014
- Last updated
- 25 Oct 2019
- Results posted
- No
- Data monitoring committee
- No
- Individual data sharing
- No
Study at a glance
From the registry record, last updated by the sponsor on 25 Oct 2019. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Increasing Human Papillomavirus Vaccine Uptake in Low-Income, Ethnic Minority Adolescents in Los Angeles County
- ClinicalTrials.gov ID
- NCT02067507
- Acronym / sponsor ID
- R01CA154549-01A1
- Conditions
- Human Papilloma Virus Infection
- Keywords
- Human Papillomavirus, Immunization, Oncogenic viruses, Cervical Cancer, Health Disparities
- Study type
- Interventional
- Recruitment status
- Completed
- Enrolment
- 53,414 participants (actual)
- Lead sponsor
- University of California, Los AngelesUniversity, hospital or other
- Collaborators
- Los Angeles County Department of Public Health
- Study start
- Jun 2012
- Primary completion
- Oct 2019 (actual)
- Study completion
- Oct 2019 (actual)
- First posted
- 20 Feb 2014 (estimated)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
The primary aim of the project is to increase human papillomavirus (HPV) vaccine receipt rates among low-income, ethnic minority adolescents (girls and boys 11-17 years of age) in Los Angeles County. We will accomplish this goal by implementing and rigorously evaluating interventions in multiple venues that serve our target population, including the Los Angeles County Department of Public Health (LACDPH) and two large Federally Qualified Health Centers (FQHCs).
Our hypotheses are:
Primary hypothesis:
- The intervention group will have a higher rate of HPV vaccine initiation at follow-up compared to the control group. Secondary hypothesis:
- The intervention group will have higher vaccine completion rates (3 doses) at follow-up compared to the control group.
Detailed description
The primary aim of the project is to increase HPV vaccine receipt rates among low-income, ethnic minority adolescents (girls and boys ages 9-17 years) in LA County. We will accomplish this goal by implementing and rigorously evaluating interventions in multiple venues that serve our target population, including the Los Angeles County Department of Public Health (LACDPH) and two large Federally Qualified Health Centers (FQHCs).
Our hypotheses are:
Primary hypothesis:
- The intervention group will have a higher rate of HPV vaccine initiation at follow-up compared to the control group. Secondary hypothesis:
- The intervention group will have higher vaccine completion rates (3 doses) at follow-up compared to the control group.
Recruitment Venue 1: Los Angeles County Department of Public Health. At the LACDPH, the multi-component intervention will be directed at caregivers of age-eligible adolescents (11-17 years) and include brief individually-tailored telephone education, referral to a clinic offering low cost/free vaccine, and a mailed brochure. The control group will receive usual care and a standard Centers for Disease Control and Prevention (CDC) HPV vaccine fact sheet.
Additional secondary hypotheses for this recruitment venue include:
- The intervention group will have higher knowledge of HPV and the HPV vaccine than the control group.
- The intervention will have a greater effect on the more acculturated than less acculturated participants (moderator effect).
- The intervention will exert its effect on vaccine receipt by increasing knowledge and reducing barriers (mediator effects).
This recruitment venue will utilize a two-arm time-randomized (on-off) controlled design to assess the effect of a multi-component intervention targeting mothers and fathers, to increase HPV vaccine uptake among their adolescents (ages 11-17). Hotline users will be randomized into the intervention or control condition on an alternating (on/off) weekly schedule. Eligible participants will complete a baseline telephone interview. Immediately following the baseline interview, participants calling during intervention weeks will receive the individually-tailored multi-component intervention, including tailored education and clinic referral. A tailored print intervention will also be mailed to intervention participants. All participants will be re-contacted at 3 months and 9 months for telephone follow-up interviews. Control group participants will receive the intervention after the 9-month follow-up. Prior to study protocol implementation, about 25-50 individuals will be recruited to pre-test the baseline survey in different languages (English, Spanish, Chinese, Armenian) to ensure the baseline questionnaires are similar in content across languages and the questions are clear.
The study site will enroll men and women of diverse racial-ethnic backgrounds from the Office of Women's Health (OWH) women's health telephone hotline database. The database includes contact information about adult women LA County residents who telephoned a 1-800 hotline to receive information and referrals about women's health issues, including cervical cancer and cervical cancer screening. Male callers also use the hotline. The OWH has promoted the hotline through partnerships with over 300 community-based organizations. Recruitment of callers from the database will consist of operators calling women to invite them to be screened for study eligibility. Recruitment of new hotline callers will take place during their first contact with the hotline. Upon receiving an incoming call, operators will first respond to the caller's request using routine hotline protocols which include screening for income eligibility (<200% of poverty) for county services. Following this, operators invite the caller to be screened for study eligibility. Eligible participants will be asked to complete the baseline interview.
Callers will be randomized to the intervention or control condition on alternating weeks (on-off or time randomized design). This randomization scheme was selected in close consultation with OWH to ensure the integrity of the randomization process and minimize disruption of routine hotline operation. The telephone intervention will be delivered immediately following the baseline telephone interview to participants calling during intervention weeks. The intervention is based on the Health Behavior Framework and pilot study findings and incorporates individual-level tailoring. The three segments of the telephone intervention include: 1) basic information about the HPV vaccine; 2) individually-tailored information to address each participant's primary concerns regarding the vaccine; 3) individually-tailored referral to a local clinic where free/low cost vaccine is available.
Baseline interviews (10-15 mins) will be conducted immediately following the eligibility screener and the verbal informed consent, via a Computer Assisted Telephone Interviewing System. All eligible subjects who complete the baseline interview will receive brief (<10 mins) 3 and 9-month follow-up telephone interviews.
Following the 3-month interviews, half of intervention participants will receive a "booster" intervention wherein we will repeat the clinic referral procedure/language given during the intervention at baseline. Intervention participants will be randomized to the "booster" or no "booster" condition based on the order in which they completed the baseline survey.
Recruitment Venue 2: AltaMed Health Services Corporation. At AltaMed Health Services Corporation, the largest federally qualified health center in the nation, we will implement a multi-level intervention that includes patient (i.e., caregiver) and provider reminders, physician, nurse, and other staff training regarding the HPV vaccine and processes and procedures for its delivery. We will utilize a quasi-experimental study design to assess the effect of this multi-level intervention to increase HPV vaccine initiation and completion among adolescents (ages 9-17). Eight clinic sites that serve the majority of AltaMed's adolescent population will be matched based on the size of the adolescent population served and baseline HPV vaccination rates. We will randomly assign matched paired clinics to either the intervention (n=4) or usual care group (n=4).
Clinics assigned to the usual care condition will only receive: (1) the standing order for the HPV vaccine, which authorizes non-physician providers to assess adolescents' immunization eligibility and administer the HPV vaccine without a physician examination or order and (2) a required web-based training module for medical assistants and nurses containing basic information on HPV, the HPV vaccine, and standing order implementation.
In addition to usual care activities, intervention clinics will receive the following: (1) health care provider training on the importance of HPV vaccination and a strong provider recommendation, strategies to appropriately frame the HPV vaccine conversation, and recommended processes and procedures for vaccine delivery; (2) staff training on the importance of HPV vaccination, strategies to promote uptake of the vaccine, and recommended processes and procedures for vaccine delivery; (3) patient and provider reminders to promote completion of the three-dose vaccine series; and (4) organizational strategies to improve processes for vaccine delivery, in addition to usual care activities.
The intervention will be developed in close collaboration with administrative leadership and providers, who will provide input at each stage of the design, implementation, and evaluation process. A physician vaccine champion from the organization will assist with the development of and lead a one-hour, in-person provider presentation and discussion. For the staff training presentation, nurse managers will be convened regularly to discuss processes for HPV and general standing order implementation, strategies to optimize clinical workflow and increase follow-up, and development of back office staff training. Using a train-the-trainer approach, the nurse mangers will lead the approximate one-hour presentation and discussion at their respective clinics. They will also monitor process implementation through direct staff observation and quality reports and retrain staff as needed.
In addition to provider and staff trainings, organizational strategies at intervention sites will include implementation of standard practices for HPV vaccine delivery that complement existing clinical workflow. At intake, back office staff will check vaccination history at each visit, implement needed standing orders, inform caregivers of vaccines due, and notify the provider of vaccines ordered. During the provider encounter, providers will confirm recommended vaccinations and recommend the HPV vaccine as part of other routine vaccines. At check-out, back office staff will administer vaccines, schedule a visit for the second dose, and provide caregivers both a standard appointment card and an intervention site reminder magnet. A clinic provider vaccine champion will be identified to monitor implementation, adapt processes, and serve as a resource at intervention sites.
To estimate intervention effects, we will use data extracted from AltaMed's electronic medical record system to measure HPV vaccine initiation and completion rates among adolescents ages 9-17 at baseline and at regular intervals post intervention implementation. Patient, provider and clinic factors associated with vaccine receipt will also be examined.
Recruitment Venue 3: Northeast Valley Health Corporation. At Northeast Valley Health Corporation, another large federally qualified health center, we will implement and evaluate the effects of three different clinic-level reminder systems (mailed letter, automated/robo telephone call, text message) on HPV vaccine initiation and completion among adolescents (ages 12-13).
We will utilize a quasi-experimental study design. This FQHC comprises 8 sites that provide primary care for medically underserved adults and adolescents in LA County. We will select 6 clinics matched on baseline vaccine receipt rates and other clinic characteristics and randomly assign matched paired clinics to usual care or one of the three reminder system interventions: mailed letter, automated/robo telephone call, or text message. Eligible caregivers of adolescent boys and girls ages 12-13 who have received no doses or only one dose of the HPV vaccine will be identified through Northeast Valley's electronic medical record and population health management systems.
After identification of eligible patients (i.e. caregivers), the centralized call center will generate a standard letter and the automated/robocalls. A third-party vendor will send the text messages. The reminder content will be adapted from existing clinical message scripts and include a short message, which will be consistent across all modalities, on the importance of HPV vaccination and how to make an appointment. Reminder messages will be delivered in the patients' preferred language (either English or Spanish). The same reminder type (either letter, call, or text message) will be used on up to two occasions: once at baseline and a second time approximately one month after baseline for those who have not yet received the targeted vaccine dose. To monitor receipt of reminders, number of unaccepted telephone calls, returned letters, and stopped text messages will be monitored. Clinics assigned to the usual care condition will receive standard of care, which does not include any systematic reminders.
Similar to the AltaMed FQHC site, to estimate intervention effects, we will use data extracted from electronic medical records to measure HPV vaccine initiation and completion rates at baseline and at regular intervals post intervention implementation.
Study design
- Primary purpose
- Prevention
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- None (open label)
- Number of arms
- 4
| Arm | Type | Receives |
|---|---|---|
| Control | No intervention | –LACDPH Site: CDC-developed small media in preferred language AltaMed Health Services Corporation Site: Usual care - Standing order for the HPV vaccine; required web-based training module for medical assistants and nurses containing basic information on HPV, the HPV vaccine, and standing order implementation Northeast Valley Health Corporation Site: Usual care |
| Tailored education and referral | Experimental | Behavioral: Tailored education and referralLACDPH Site: Tailored education and referral intervention administered at LACDPH Site |
| Staff training and patient reminders | Experimental | Behavioral: Staff training and patient remindersStaff training and patient reminders administered at AltaMed Health Services Corporation Site |
| Clinic-level reminder systems | Experimental | Behavioral: Clinic-level reminder systemsClinic-level reminders administered at Northeast Valley Health Corporation Site |
Who may qualify
- Ages
- 9 to 70 years
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Child, Adult, Older adult
Key inclusion criteria (11 listed)
- Adult male or female
- Current or previous user of the Los Angeles County Office of Women's Health Hotline
- Speaks one of the hotline languages (English, Spanish, Korean, Mandarin, Cantonese, Armenian)
- Is the medical decision-maker for a male or female adolescent aged 11-17 in his or her home
- Adolescent has not started the HPV vaccine series
Key exclusion criteria (12 listed)
- Younger than 18 or older than 70 years of age
- Not conversant in one of the hotline languages (English, Spanish, Korean, Mandarin, Cantonese, Armenian)
- Is not the medical decision-maker for an adolescent aged 11-17 in his or her home
- Adolescent has initiated the HPV vaccine series
- Not a current resident of Los Angeles County
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Tailored education and referralLACDPH Site: 5-minute tailored educational messages and clinic referral for vaccine plus tailored small media | Behavioural | Tailored education and referral |
| Staff training and patient remindersAltaMed Health Services Corporation Site: (1) Health care provider training on the importance of HPV vaccination, strategies to appropriately frame the HPV vaccine conversation, and recommended processes and procedures for vaccine delivery; (2) Staff training on the importance of HPV vaccination, strategies to promote uptake of the vaccine, and recommended processes and procedures for vaccine delivery; (3) Patient reminders and provider cues for follow-up doses; and (4) Organizational strategies to improve processes for vaccine delivery, in addition to usual care activities | Behavioural | Staff training and patient reminders |
| Clinic-level reminder systemsNortheast Valley Health Corporation Site: Three different clinic-level reminder systems, including a mailed letter, automated/robo telephone call, or text message reminder | Behavioural | Clinic-level reminder systems |
Primary outcome
HPV Vaccine Uptake
Time frame: 3 months, 6 months
The receipt of one or more doses of the HPV vaccine
1 secondary outcome
HPV Vaccine Series Completion
Time frame: 9 months, 12 months
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 25 Oct 2019.
- Individual participant dataSharing planned: No
Related trials for Human Papilloma Virus Infection
Not yet recruitingPhase 1/2
Clinical Trial to Assess the Safety, Tolerability, Reactogenicity, and Immunogenicity of a 10 Valent Human Papillomavirus Virus (10vHPV) Vaccine
Human Papillomavirus Infection
Active, not recruitingPhase 4
Comparing Immune Response of 2 vs 3 HPV Doses (27-45 Years Old)
Immunization, HPV Infection
Not yet recruitingPhase 2
Combination Bevacizumab and PRGN-2012 in Adults With Recurrent Respiratory Papillomatosis (RRP)
Respiratory Recurrent Papillomatosis (RRP), Human Papillomavirus (HPV)
RecruitingPhase 2
A Study of the Preliminary Efficacy of DARE-HPV to Treat High-risk Persistent Human Papillomavirus (hrHPV)
Human Papilloma Virus (HPV), High-risk Human Papillomavirus Infection
RecruitingPhase 2
A Single Arm Phase II Trial in p16-positive Oropharynx Cancer of Selective Dose De-escalation of nodAl VolumEs at Minimal Risk and Primary Site Disease (SAVED)
Head and Neck Cancer, Head and Neck Squamous Cell Cancer
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Roshan Bastani, PhD principal investigator
University of California, Los Angeles
Beth Glenn, PhD study director
University of California, Los Angeles
2 sites in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing Tailored education and referral, Staff training and patient reminders and Clinic-level reminder systems in people with Human Papilloma Virus Infection, run by University of California, Los Angeles at 2 sites in United States.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 11 inclusion and 12 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 25 Oct 2019. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 2 sites in United States. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
HPV Vaccine Uptake (time frame: 3 months, 6 months). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 25 Oct 2019.